Literature DB >> 33728763

Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during mid- and late-gestation by platelet TFPIα overexpression.

Amy E Siebert1, Susan A Maroney1, Nicholas D Martinez1, Alan E Mast1,2.   

Abstract

BACKGROUND: Tissue factor pathway inhibitor (TFPI) is an anticoagulant protein required for murine embryonic development. Intrauterine lethality of Tfpi-/- mice occurs at mid- and late gestation, the latter of which is associated with severe cerebrovascular defects. Megakaryocytes produce only the TFPIα isoform, which is stored within platelets and released upon activation.
OBJECTIVES: To examine biological activities of platelet TFPIα (pTFPIα) by characterizing effects of pTFPIα overexpression in Tfpi-/- mice.
METHODS: Transgenic mice overexpressing pTFPIα were generated and crossed onto the Tfpi-/- background. Genetic and histological analyses of embryos were performed to investigate the function of pTFPIα during embryogenesis.
RESULTS: The transgene (Tg) increased pTFPIα 4- to 5-fold without altering plasma TFPI in adult Tfpi+/+ and Tfpi+/- mice but did not rescue Tfpi-/- mice to wean. Analyses of the impact of pTFPIα overexpression on Tfpi-/- survival, however, were complicated by linkage between the Tg integration site and the endogenous Tfpi locus on chromosome 2. Strain-specific genetic interactions also modulated Tfpi-/- embryonic survival. After accounting for these underlying genetic factors, pTFPIα overexpression completely suppressed mid-gestational lethality of Tfpi-/- embryos but had no effect on development of cerebrovascular defects during late gestation resulting in their lack of survival to wean.
CONCLUSIONS: pTFPIα overexpression rescued Tfpi-/- embryos from mid-gestational but not late gestational lethality. The prevalence of underlying genetic factors complicating analyses within our study illustrates the importance of meticulously characterizing transgenic mouse models to avoid spurious interpretation of results.
© 2021 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  TFPI; embryogenesis; platelets; transgene

Mesh:

Substances:

Year:  2021        PMID: 33728763      PMCID: PMC8165032          DOI: 10.1111/jth.15299

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   16.036


  46 in total

1.  Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.

Authors:  L C Petersen; S E Bjørn; O H Olsen; O Nordfang; F Norris; K Norris
Journal:  Eur J Biochem       Date:  1996-01-15

2.  A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice.

Authors:  Brian Pedersen; Todd Holscher; Yuichiro Sato; Rafal Pawlinski; Nigel Mackman
Journal:  Blood       Date:  2004-12-14       Impact factor: 22.113

3.  p45NF-E2 represses Gcm1 in trophoblast cells to regulate syncytium formation, placental vascularization and embryonic growth.

Authors:  Muhammed Kashif; Andrea Hellwig; Alexandre Kolleker; Khurrum Shahzad; Hongjie Wang; Siegfried Lang; Juliane Wolter; Madhusudhan Thati; Ilya Vinnikov; Angelika Bierhaus; Peter P Nawroth; Berend Isermann
Journal:  Development       Date:  2011-06       Impact factor: 6.868

4.  TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene.

Authors:  J Y Chang; D M Monroe; J A Oliver; H R Roberts
Journal:  Thromb Haemost       Date:  1999-01       Impact factor: 5.249

5.  Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.

Authors:  O Nordfang; S Valentin; T C Beck; U Hedner
Journal:  Thromb Haemost       Date:  1991-10-01       Impact factor: 5.249

6.  Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors.

Authors:  J Gewirtz; M A Thornton; L Rauova; M Poncz
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

7.  Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

Authors:  Michelle M Castillo; Qiuhui Yang; Min Zhan; Amy Y Pan; Michael W Lawlor; Alan E Mast; Rashmi Sood
Journal:  Blood Adv       Date:  2019-02-12

8.  Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell.

Authors:  Amy E Siebert; Alan E Mast
Journal:  J Thromb Haemost       Date:  2020-07-30       Impact factor: 5.824

9.  A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.

Authors:  Paul E R Ellery; Susan A Maroney; Brian C Cooley; James P Luyendyk; Mark Zogg; Hartmut Weiler; Alan E Mast
Journal:  Blood       Date:  2015-05-07       Impact factor: 22.113

10.  Tissue factor pathway inhibitor is required for cerebrovascular development in mice.

Authors:  Susan A Maroney; Randal J Westrick; Audrey C Cleuren; Nicholas D Martinez; Amy E Siebert; Mark Zogg; David Ginsburg; Hartmut Weiler; Alan E Mast
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

View more
  2 in total

1.  The contribution of TFPIα to the hemostatic response to injury in mice.

Authors:  Tanya T Marar; Nicholas D Martinez; Susan A Maroney; Amy E Siebert; Jie Wu; Timothy J Stalker; Maurizio Tomaiuolo; Sinny Delacroix; Robert D Simari; Alan E Mast; Lawrence F Brass
Journal:  J Thromb Haemost       Date:  2021-07-14       Impact factor: 16.036

Review 2.  Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.

Authors:  Alan E Mast; Wolfram Ruf
Journal:  J Thromb Haemost       Date:  2022-03-27       Impact factor: 16.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.